Tonix starts dosing patients in migraine drug study
Tweet Send to a Friend
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that the first participant has been dosed in a Phase 1 study evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


